<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03036826</url>
  </required_header>
  <id_info>
    <org_study_id>ABX-TDM-CVVHD</org_study_id>
    <nct_id>NCT03036826</nct_id>
  </id_info>
  <brief_title>Computer-based Dosage Calculation for Antibiotics</brief_title>
  <official_title>Computer-basierte Dosierungsregime Von Antiinfektiva Unter Der Behandlung Mit Einem Kontinuierlichen Nierenersatztherapieverfahren</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adequate dosing of antiinfective therapy in critically ill patients with impaired or lost
      renal function and continuous renal replacement therapy is nearly impossible without
      measuring the drug concentration in blood samples. In many hospitals that is not an option.
      The investigators aim to show, that computer based calculation can avoid over- or
      under-dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adequate dosing of antiinfective therapy in critically ill patients is most important to
      improve outcome. Patients with impaired or lost renal function and continuous renal
      replacement therapy are hard to calculate using drug information sheets or &quot;lists&quot; with
      recommendations. It is nearly impossible to avoid much to low or much to high druck levels
      without measuring the concentration in blood samples. Since that possibility is not available
      in every clinic we aim to show, how a computer based calculation can help to find the
      adequate dosing.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>drug levels (blood)</measure>
    <time_frame>7 days</time_frame>
    <description>achieved drug levels in blood samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>dosing changes</measure>
    <time_frame>7 days</time_frame>
    <description>dose adjustments to the computer based calculated regiments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infections</measure>
    <time_frame>7 days</time_frame>
    <description>new infections or persistent infections while undergoing antiinfective therapy</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Acute Kidney Insufficiency</condition>
  <condition>Anti-Infective Agent Toxicity</condition>
  <arm_group>
    <arm_group_label>Piperacillin/Tazobactam</arm_group_label>
    <description>Group of patients receiving Piperacillin/Tazobactam as antiinfective therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <description>Group of patients receiving Meropenem as antiinfective therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <description>Group of patients receiving Vancomycin as antiinfective therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/tazobactam</intervention_name>
    <description>antiinfective therapy with Piperacillin/Tazobactam within routine care</description>
    <arm_group_label>Piperacillin/Tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>antiinfective therapy with Meropenem within routine care</description>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>antiinfective therapy with vancomycin within routine care</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        critically ill patients with continous renal replacement therapy and antiinfective therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written consent

          -  patients requiering antiinfective therapy

          -  patients requiering continuous renal replacement therapy

        Exclusion Criteria:

          -  participation in another clinical trial

          -  pregnancy, breast feeding

          -  inability to give consent

          -  no consent given
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefanie Prohaska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefanie Prohaska, MD</last_name>
    <phone>+49707129</phone>
    <phone_ext>86724</phone_ext>
    <email>stefanie.prohaska@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helene A Haeberle, PD</last_name>
    <phone>+49707129</phone>
    <phone_ext>86939</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2017</study_first_submitted>
  <study_first_submitted_qc>January 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2017</study_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

